Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma

Free Radical Biology and Medicine

Volumn 106, Issue , 2017, Pages 91-99

  Chew, Shan Hwu ^a   Okazaki, Yasumasa ^a   Akatsuka, Shinya ^a   Wang, Shenqi ^a   Jiang, Li ^a   Ohara, Yuuki ^a   Ito, Fumiya ^a   Saya, Hideyuki ^b   Sekido, Yoshitaka ^c   Toyokuni, Shinya ^a,d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CD44; Glutathione; Malignant mesothelioma; Nrf2; Oxidative stress

Indexed keywords

CARRIER PROTEIN; CD44V ANTIGEN; CD44V10 ANTIGEN; CD44V8 ANTIGEN; CD44V9 ANTIGEN; GLUTAMATE CYSTEINE LIGASE; GLUTAMATE CYSTEINE LIGASE CATALYTIC SUBUNIT; GLUTATHIONE; HERMES ANTIGEN; MERLIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; X CT PROTEIN; AMINO ACID TRANSPORTER; CD44 PROTEIN, HUMAN; GCLC PROTEIN, HUMAN; HYALURONIC ACID BINDING PROTEIN; ISOPROTEIN; NFE2L2 PROTEIN, HUMAN; SLC7A11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENE SILENCING; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIOMA CELL LINE; MESOTHELIUM CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HUMANS; HYALURONAN RECEPTORS; LUNG NEOPLASMS; MESOTHELIOMA; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTEIN ISOFORMS; TRANSCRIPTION FACTOR AP-1;

EID: 85012077977     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.02.011     Document Type: Article

References (61)

1. [1] Wagner, J.C., Sleggs, C.A., Marchand, P., Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 17 (1960), 260–271.
2. [2] Stanton, M.F., Wrench, C., Mechanisms of mesothelioma induction with asbestos and fibrous glass. J. Natl. Cancer Inst. 48 (1972), 797–821.
3. [3] Toyokuni, S., Mechanisms of asbestos-induced carcinogenesis. Nagoya J. Med. Sci. 71 (2009), 1–10.
4. [4] IARC, WHO. Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens; Part C: Arsenic, Metals, Fibres, and Dusts. Lyon, France; 2012: pp. 219–309.
5. [5] Takagi, A., Hirose, A., Nishimura, T., Fukumori, N., Ogata, A., Ohashi, N., Kitajima, S., Kanno, J., Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J. Toxicol. Sci. 33 (2008), 105–116.
6. [6] Nagai, H., Okazaki, Y., Chew, S.H., Misawa, N., Yamashita, Y., Akatsuka, S., Ishihara, T., Yamashita, K., Yoshikawa, Y., Yasui, H., Jiang, L., Ohara, H., Takahashi, T., Ichihara, G., Kostarelos, K., Miyata, Y., Shinohara, H., Toyokuni, S., Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proc. Natl. Acad. Sci. USA 108 (2011), E1330–E1338.
7. [7] Toyokuni, S., Genotoxicity and carcinogenicity risk of carbon nanotubes. Adv. Drug Deliv. Rev. 65 (2013), 2098–2110.
8. [8] Wang, Y., Okazaki, Y., Shi, L., Kohda, H., Tanaka, M., Taki, K., Nishioka, T., Hirayama, T., Nagasawa, H., Yamashita, Y., Toyokuni, S., Role of hemoglobin and transferrin in multi-wall carbon nanotube-induced mesothelial injury and carcinogenesis. Cancer Sci. 107 (2016), 250–257.
9. [9] Rascoe, P.A., Jupiter, D., Cao, X., Littlejohn, J.E., Smythe, W.R., Molecular pathogenesis of malignant mesothelioma. Expert Rev. Mol. Med., 14, 2012, e12.
10. [10] Chew, S.H., Toyokuni, S., Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic. Biol. Med. 86 (2015), 166–178.
11. [11] Ali, G., Borrelli, N., Riccardo, G., Proietti, A., Pelliccioni, S., Niccoli, C., Boldrini, L., Lucchi, M., Mussi, A., Fontanini, G., Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J. Thorac. Oncol. 8 (2013), 1389–1395.
12. [12] Ponta, H., Sherman, L., Herrlich, P.A., CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4 (2003), 33–45.
13. [13] Zoller, M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 11 (2011), 254–267.
14. [14] Penno, M.B., Askin, F.B., Ma, H., Carbone, M., Vargas, M.P., Pass, H.I., High CD44 expression on human mesotheliomas mediates association with hyaluronan. Cancer J. Sci. Am. 1 (1995), 196–203.
15. [15] Thylen, A., Wallin, J., Martensson, G., Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer 86 (1999), 2000–2005.
16. [16] Pettersson, T., Froseth, B., Riska, H., Klockars, M., Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 94 (1988), 1037–1039.
17. [17] Creaney, J., Dick, I.M., Segal, A., Musk, A.W., Robinson, B.W., Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 82 (2013), 491–498.
18. [18] van der Voort, R., Manten-Horst, E., Smit, L., Ostermann, E., van den Berg, F., Pals, S.T., Binding of cell-surface expressed CD44 to hyaluronate is dependent on splicing and cell type. Biochem. Biophys. Res. Commun. 214 (1995), 137–144.
19. [19] Iida, N., Bourguignon, L.Y., Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. J. Cell Physiol. 171 (1997), 152–160.
20. [20] Asplund, T., Heldin, P., Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 54 (1994), 4516–4523.
21. [21] Nasreen, N., Mohammed, K.A., Hardwick, J., Van Horn, R.D., Sanders, K., Kathuria, H., Loghmani, F., Antony, V.B., Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol. Res. 13 (2002), 71–78.
22. [22] Cortes-Dericks, L., Froment, L., Boesch, R., Schmid, R.A., Karoubi, G., Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. BMC Cancer, 14, 2014, 304.
23. [23] Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., Masuko, T., Shimizu, T., Ishikawa, T., Kai, K., Takahashi, E., Imamura, Y., Baba, Y., Ohmura, M., Suematsu, M., Baba, H., Saya, H., CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19 (2011), 387–400.
24. [24] Warzecha, C.C., Sato, T.K., Nabet, B., Hogenesch, J.B., Carstens, R.P., ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell 33 (2009), 591–601.
25. [25] Yae, T., Tsuchihashi, K., Ishimoto, T., Motohara, T., Yoshikawa, M., Yoshida, G.J., Wada, T., Masuko, T., Mogushi, K., Tanaka, H., Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun., 3, 2012, 883.
26. [26] Usami, N., Fukui, T., Kondo, M., Taniguchi, T., Yokoyama, T., Mori, S., Yokoi, K., Horio, Y., Shimokata, K., Sekido, Y., Hida, T., Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 97 (2006), 387–394.
27. [27] Taniguchi, T., Karnan, S., Fukui, T., Yokoyama, T., Tagawa, H., Yokoi, K., Ueda, Y., Mitsudomi, T., Horio, Y., Hida, T., Yatabe, Y., Seto, M., Sekido, Y., Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 98 (2007), 438–446.
28. [28] Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., Akatsuka, S., Horio, Y., Hida, T., Kondo, Y., Toyokuni, S., Osada, H., Sekido, Y., LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71 (2011), 873–883.
29. [29] Sekido, Y., Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol. Int. 61 (2011), 331–344.
30. [30] Tanabe, K.K., Ellis, L.M., Saya, H., Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341 (1993), 725–726.
31. [31] Rall, C.J., Rustgi, A.K., CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res. 55 (1995), 1831–1835.
32. [32] Muramaki, M., Miyake, H., Kamidono, S., Hara, I., Over expression of CD44V8-10 in human bladder cancer cells decreases their interaction with hyaluronic acid and potentiates their malignant progression. J. Urol. 171 (2004), 426–430.
33. [33] Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., Onishi, N., Masuko, T., Yoshizawa, K., Kawashiri, S., Mukai, M., Asoda, S., Kawana, H., Nakagawa, T., Saya, H., Nagano, O., xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 73 (2013), 1855–1866.
34. [34] Zeilstra, J., Joosten, S.P., van Andel, H., Tolg, C., Berns, A., Snoek, M., van de Wetering, M., Spaargaren, M., Clevers, H., Pals, S.T., Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene 33 (2013), 665–670.
35. [35] Nagano, O., Okazaki, S., Saya, H., Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 32 (2013), 5191–5198.
36. [36] Lau, W.M., Teng, E., Chong, H.S., Lopez, K.A., Tay, A.Y., Salto-Tellez, M., Shabbir, A., So, J.B., Chan, S.L., CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 74 (2014), 2630–2641.
37. [37] Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H.J., van Es, J.H., Sato, T., Stange, D.E., Begthel, H., van den Born, M., Danenberg, E., van den Brink, S., Korving, J., Abo, A., Peters, P.J., Wright, N., Poulsom, R., Clevers, H., Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6 (2010), 25–36.
38. [38] Jiang, L., Yamashita, Y., Chew, S.H., Akatsuka, S., Ukai, S., Wang, S., Nagai, H., Okazaki, Y., Takahashi, T., Toyokuni, S., Connective tissue growth factor and beta-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma. J. Pathol. 233 (2014), 402–414.
39. [39] Uematsu, K., Kanazawa, S., You, L., He, B., Xu, Z., Li, K., Peterlin, B.M., McCormick, F., Jablons, D.M., Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 63 (2003), 4547–4551.
40. [40] Mazieres, J., You, L., He, B., Xu, Z., Twogood, S., Lee, A.Y., Reguart, N., Batra, S., Mikami, I., Jablons, D.M., Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int. J. Cancer 117 (2005), 326–332.
41. [41] Kuniyasu, H., Oue, N., Tsutsumi, M., Tahara, E., Yasui, W., Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin. Cancer Res. 7 (2001), 4067–4072.
42. [42] Wang, S.J., Bourguignon, L.Y., Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am. J. Pathol. 178 (2011), 956–963.
43. [43] Mulder, J.W., Kruyt, P.M., Sewnath, M., Oosting, J., Seldenrijk, C.A., Weidema, W.F., Offerhaus, G.J., Pals, S.T., Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344 (1994), 1470–1472.
44. [44] Yamamichi, K., Uehara, Y., Kitamura, N., Nakane, Y., Hioki, K., Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int. J. Cancer 79 (1998), 256–262.
45. [45] Yamaguchi, A., Goi, T., Yu, J., Hirono, Y., Ishida, M., Iida, A., Kimura, T., Takeuchi, K., Katayama, K., Hirose, K., Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J. Surg. Oncol. 79 (2002), 230–235.
46. [46] Khan, S.A., Cook, A.C., Kappil, M., Gunthert, U., Chambers, A.F., Tuck, A.B., Denhardt, D.T., Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin. Exp. Metastas. 22 (2005), 663–673.
47. [47] Ue, T., Yokozaki, H., Kitadai, Y., Yamamoto, S., Yasui, W., Ishikawa, T., Tahara, E., Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer 79 (1998), 127–132.
48. [48] Hirata, K., Suzuki, H., Imaeda, H., Matsuzaki, J., Tsugawa, H., Nagano, O., Asakura, K., Saya, H., Hibi, T., CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br. J. Cancer 109 (2013), 379–386.
49. [49] Katoh, S., Goi, T., Naruse, T., Ueda, Y., Kurebayashi, H., Nakazawa, T., Kimura, Y., Hirono, Y., Yamaguchi, A., Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Anticancer Res. 35 (2015), 239–244.
50. [50] Sekido, Y., Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34 (2013), 1413–1419.
51. [51] Zhang, N., Bai, H., David, K.K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R.A., Pan, D., The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19 (2010), 27–38.
52. [52] Mizuno, T., Murakami, H., Fujii, M., Ishiguro, F., Tanaka, I., Kondo, Y., Akatsuka, S., Toyokuni, S., Yokoi, K., Osada, H., Sekido, Y., YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 31 (2012), 5117–5122.
53. [53] Seishima, R., Wada, T., Tsuchihashi, K., Okazaki, S., Yoshikawa, M., Oshima, H., Oshima, M., Sato, T., Hasegawa, H., Kitagawa, Y., Ink4a/Arf-dependent loss of parietal cells induced by oxidative stress promotes CD44-dependent gastric tumorigenesis. Cancer Prev. Res. 8 (2015), 492–501.
54. [54] Yae, T., Tsuchihashi, K., Ishimoto, T., Motohara, T., Yoshikawa, M., Yoshida, G.J., Wada, T., Masuko, T., Mogushi, K., Tanaka, H., Osawa, T., Kanki, Y., Minami, T., Aburatani, H., Ohmura, M., Kubo, A., Suematsu, M., Takahashi, K., Saya, H., Nagano, O., Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun., 3, 2012, 883.
55. [55] Lu, S.C., Regulation of glutathione synthesis. Mol. Asp. Med. 30 (2009), 42–59.
56. [56] Tajima, K., Ohashi, R., Sekido, Y., Hida, T., Nara, T., Hashimoto, M., Iwakami, S., Minakata, K., Yae, T., Takahashi, F., Saya, H., Takahashi, K., Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene 29 (2010), 1941–1951.
57. [57] Toyokuni, S., Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 100 (2009), 9–16.
58. [58] Nagai, H., Ishihara, T., Lee, W.H., Ohara, H., Okazaki, Y., Okawa, K., Toyokuni, S., Asbestos surface provides a niche for oxidative modification. Cancer Sci. 102 (2011), 2118–2125.
59. [59] Jiang, L., Akatsuka, S., Nagai, H., Chew, S.H., Ohara, H., Okazaki, Y., Yamashita, Y., Yoshikawa, Y., Yasui, H., Ikuta, K., Sasaki, K., Kohgo, Y., Hirano, S., Shinohara, Y., Kohyama, N., Takahashi, T., Toyokuni, S., Iron overload signature in chrysotile-induced malignant mesothelioma. J. Pathol. 228 (2012), 366–377.
60. [60] Toyokuni, S., Oxidative stress as an iceberg in carcinogenesis and cancer biology. Arch. Biochem. Biophys. 595 (2016), 46–49.
61. [61] Toyokuni, S., Iron and thiols as two major players in carcinogenesis: friends or foes?. Front. Pharmacol., 5, 2014, 200.